TY - JOUR
T1 - Emerging therapeutic targets and strategies in Crohn’s disease
AU - Furfaro, Federica
AU - Fiorino, Gionata
AU - Allocca, Mariangela
AU - Gilardi, Daniela
AU - Danese, Silvio
PY - 2016/2/15
Y1 - 2016/2/15
N2 - Crohn’s disease (CD) is an immune-mediated inflammatory bowel disease, in which inflammation is driven by a complex interaction between the microbiota, immune cells, genes and mediators. New mechanisms of action and several cytokines have been identified as factors involved in the inflammatory process in CD, and many new molecules have been developed to treat this complex disease. New agents have been developed that target leukocyte trafficking, block or adhesion molecules for example, as well as the development of antibodies against classic inflammatory cytokines or therapies directed against IL-12/23 and Janus kinases. The development of selective mechanisms of action and targeting of different cytokines or inflammatory mediators for each patient presents the biggest challenge for the future in CD therapy. Such agents are currently at different phases of development. We aim to review the current literature data on a targeted approach in CD, which could be promising alternative approach for CD patients in the near future.
AB - Crohn’s disease (CD) is an immune-mediated inflammatory bowel disease, in which inflammation is driven by a complex interaction between the microbiota, immune cells, genes and mediators. New mechanisms of action and several cytokines have been identified as factors involved in the inflammatory process in CD, and many new molecules have been developed to treat this complex disease. New agents have been developed that target leukocyte trafficking, block or adhesion molecules for example, as well as the development of antibodies against classic inflammatory cytokines or therapies directed against IL-12/23 and Janus kinases. The development of selective mechanisms of action and targeting of different cytokines or inflammatory mediators for each patient presents the biggest challenge for the future in CD therapy. Such agents are currently at different phases of development. We aim to review the current literature data on a targeted approach in CD, which could be promising alternative approach for CD patients in the near future.
KW - anti-adhesion molecules
KW - anti-cytokine
KW - biologics
KW - Crohn’s disease
KW - small molecules
UR - http://www.scopus.com/inward/record.url?scp=84958523428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958523428&partnerID=8YFLogxK
U2 - 10.1586/17474124.2016.1142372
DO - 10.1586/17474124.2016.1142372
M3 - Article
AN - SCOPUS:84958523428
SP - 1
EP - 10
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
SN - 1747-4124
ER -